ProKidney Corp. (NASDAQ:PROK) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by on Jul 5th, 2026

ProKidney Corp. (NASDAQ:PROK – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

Several analysts have weighed in on PROK shares. Weiss Ratings lowered shares of ProKidney from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of ProKidney in a research report on Monday, May 18th. Jefferies Financial Group raised shares of ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of ProKidney from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th.

Check Out Our Latest Analysis on ProKidney

Hedge Funds Weigh In On ProKidney

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new position in shares of ProKidney during the first quarter valued at $25,000. SummitTX Capital L.P. acquired a new stake in shares of ProKidney in the 1st quarter worth about $26,000. Cetera Investment Advisers acquired a new stake in shares of ProKidney in the 4th quarter worth about $28,000. AQR Capital Management LLC lifted its position in ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after purchasing an additional 27,098 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in ProKidney in the 4th quarter valued at about $65,000. 51.59% of the stock is owned by institutional investors.

ProKidney Price Performance

PROK opened at $2.03 on Tuesday. ProKidney has a 12-month low of $0.59 and a 12-month high of $7.13. The stock has a market capitalization of $613.18 million, a PE ratio of -3.83 and a beta of 1.61. The firm’s fifty day moving average price is $1.80 and its 200 day moving average price is $2.01.

ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.10 million. On average, equities research analysts forecast that ProKidney will post -0.49 earnings per share for the current fiscal year.

ProKidney Company Profile

(Get Free Report)

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.

Featured Articles

Analyst Recommendations for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.